PRF Technologies Ltd. Ordinary Shares (PRFX)

FairStock Score: 45/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

PRF Technologies, formerly PainReform, is a specialty pharmaceutical company based in Israel with just six employees. It is developing OcuRing-K for cataract surgery and PRF-110 for post-operative pain. At the 2026-10-13 close of $0.82, its market cap is only $2.0 million, so this is a micro-cap where survival and pipeline news matter more than current profits. FairStock calculations show a negative P/E of -0.20, P/B of 0.08, ROE of -45.33%, and ROCE of -21.88%. The debt-to-equity ratio is 0.00, so there is no reported debt, which is a modest positive. But the Piotroski F-Score is 0/9 and the Altman Z-Score is -6.52, both pointing to severe financial weakness or distress. The low P/B might attract a Graham-style asset hunter, yet with negative returns on equity and capital, the book value may not represent durable earning power. No revenue growth or profit growth data is provided, and the Lynch category is none because only 0 years of filed results are available, versus the 3 required. The 52-week range of $0.81 to $7.95 shows a collapse toward the low. The FairStock Score is 45/100. As an investor in the Buffett-Graham tradition, I want a business with a durable competitive advantage, consistent earnings, and a margin of safety. Here, the cheap statistical price is offset by tiny scale, no proven earning record, and high uncertainty. The company could succeed if its products advance, but today the numbers describe a weak, speculative enterprise, not a proven value.

In plain English: PRF Technologies is a tiny Israeli specialty drug company with six employees, working on eye-surgery pain and drug-delivery products called OcuRing-K and PRF-110. The business looks weak: it is losing money, has no meaningful reported growth to judge, and its financial health scores are poor. The stock price looks very low compared with its accounting value, but that cheapness comes with very high risk because the company is small, unprofitable, and has almost no filing history.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer